Form 4: Tonix Pharmaceuticals Director Receives Stock Options

Director David L. Grange was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Summary

• Director David L. Grange received a grant of 22,700 stock options on May 12, 2026.
• The options have an exercise price of $13.28 per share.
• The grant is part of the Issuer's 2026 Stock Incentive Plan.
• The options vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $13.28 exercise price.

Future Outlook

The options vest in one year, signaling a long-term retention strategy for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with corporate milestones and long-term performance.

Comparison to Industry Standards

• The use of a one-year vesting schedule is consistent with standard corporate governance practices for non-employee director compensation in small-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 12, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Form 4, Insider Trading, Stock Options, Director Compensation